whitepaper
Whitepaper: Impact of a pandemic outbreak on vaccine development approach
This whitepaper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods will not solve.
List view / Grid view
Vaccines
article
Developing drug pipelines
Kris Sterkens, Company Group Chairman of Janssen EMEA and Managing Director of Janssen Pharmaceutica considers how alterations made to COVID-19 vaccine development procedures could benefit future drug development pipelines.
whitepaper
Press release: Telstar: 360 degrees GMP consultancy & engineering solutions at CPhI
Telstar promotes innovative aseptic production solutions in a setting marked by the new GMP Annex 1.
video
On-demand webinar: High speed for your material analysis
In this webinar, discover how an innovative 2-in-1 method for material analysis accelerates visual and chemical particle analysis in the pharmaceutical industry.
whitepaper
Flyer: Efficient root cause analysis of foreign particles in pharmaceutical products
This flyer explains step-by-step how to perform your root cause analysis more efficiently, reliably and cost-effectively with a 2-in-1 solution for visual and chemical particle analysis.
whitepaper
eGuide: How to quickly identify contaminants in pharma
In this eGuide you will learn about an innovative 2-in-1 method for materials analysis and how your analysis for contamination identification and root cause analysis will benefit.
news
FDA authorises Comirnaty® for emergency use in five to 11 year olds
The US Food and Drug Administration has authorised the emergency use of COVID-19 vaccine Comirnaty in children aged five to 11 years.
news
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, Oct 2021
EMA's drug safety committee (PRAC) assessed risks with COVID-19 vaccines and identified no risk of death with Imbruvica and ACE inhibitors.
news
CHMP recommends COVID-19 vaccine Spikevax booster dose
The European Medicines Agency (EMA)'s human medicines committee (CHMP) concludes that a booster dose of Spikevax can be administered in adults aged 18 or over.
article
Co-creating solutions that advance global health innovation – IFPMA’s role
The COVID-19 pandemic has altered and continues to shape our lives. Here, Thomas B Cueni, Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), gives insight into how the pandemic gave impetus to the organisation’s manifesto to innovate and save lives.
news
Comirnaty® booster dose displays high efficacy in Phase III study
The vaccine showed a relative vaccine efficacy of 95.6 percent and is the first efficacy results from a COVID-19 vaccine booster trial.
news
Stabiliser-free PLGA nanoparticle formulation shows promise for drug delivery
Scientists have developed a stabiliser-free, non-toxic poly(lactic-co-glycolic acid) (PLGA) nanoparticle formulation for use in drug and vaccine delivery.
news
Heterologous COVID-19 booster doses show 68 percent effectiveness
A Swedish study found that heterologous Vaxzevria and mRNA prime-boost vaccination is effective against COVID-19.
whitepaper
Whitepaper: Faster isolation of PBMC with Centrifuge 5910 Ri
Save up to 88% of deceleration time for your PBMC isolation due to optimized breaking ramps of Eppendorf Centrifuge 5910 Ri.
podcasts
EPR Podcast Episode 4 – UV/Vis in mRNA vaccine QC with Dr Hans-Joachim Muhr, Mettler Toledo
Join Mettler Toledo's Dr Hans-Joachim Muhr as he explains the key quality considerations for mRNA vaccines and why UV/Vis spectrophotometry should be applied in their QA/QC.
